Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $1000.0.

  • Cue Biopharma's Cash from Financing Activities fell 9998.98% to $1000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 million, marking a year-over-year decrease of 56.4%. This contributed to the annual value of $10.2 million for FY2024, which is 1363.41% down from last year.
  • As of Q3 2025, Cue Biopharma's Cash from Financing Activities stood at $1000.0, which was down 9998.98% from $17.8 million recorded in Q2 2025.
  • Cue Biopharma's Cash from Financing Activities' 5-year high stood at $27.4 million during Q4 2022, with a 5-year trough of -$1.0 million in Q2 2024.
  • Its 5-year average for Cash from Financing Activities is $5.9 million, with a median of $2.4 million in 2024.
  • In the last 5 years, Cue Biopharma's Cash from Financing Activities soared by 5108888.89% in 2023 and then tumbled by 14759.64% in 2024.
  • Cue Biopharma's Cash from Financing Activities (Quarter) stood at $7.4 million in 2021, then skyrocketed by 271.2% to $27.4 million in 2022, then crashed by 82.55% to $4.8 million in 2023, then tumbled by 119.49% to -$932000.0 in 2024, then skyrocketed by 100.11% to $1000.0 in 2025.
  • Its Cash from Financing Activities stands at $1000.0 for Q3 2025, versus $17.8 million for Q2 2025 and -$1.0 million for Q1 2025.